Clinical Trials Logo

Filter by:
NCT ID: NCT05348577 Recruiting - Prostate Cancer Clinical Trials

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

CAPItello280
Start date: March 25, 2022
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival of study participants, when overall survival is defined as the time from randomization until the date of death due to any cause.

NCT ID: NCT05347147 Terminated - Clinical trials for Idiopathic Intracranial Hypertension

A Trial to Determine the Efficacy and Safety of Presendin in IIH

IIH EVOLVE
Start date: November 18, 2022
Phase: Phase 3
Study type: Interventional

Idiopathic intracranial hypertension (IIH) has significant associated morbidity and reduced quality of life. There is a significant risk of visual loss and patients also typically suffer with chronic disabling headaches. This trial has been designed to evaluate the efficacy and safety of a new formulation of exenatide (Presendin) in the reduction of intracranial pressure (ICP) in patients with IIH.

NCT ID: NCT05347095 Recruiting - Clinical trials for Perianal Crohns Disease

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

FUZION CD
Start date: September 27, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety of guselkumab.

NCT ID: NCT05346484 Recruiting - Solid Tumor Clinical Trials

A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

MAST
Start date: May 17, 2022
Phase: Phase 1
Study type: Interventional

This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab in patients with metastatic or advanced solid tumors.

NCT ID: NCT05345509 Recruiting - Alzheimer Disease Clinical Trials

A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.

Start date: April 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A Clinical Trial to Assess Pharmacokinetic Profiles and Safety of IVL3003

NCT ID: NCT05345327 Recruiting - Type 2 Diabetes Clinical Trials

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

START
Start date: January 1, 2023
Phase: Phase 3
Study type: Interventional

The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.

NCT ID: NCT05344170 Completed - Insomnia Disorder Clinical Trials

Cannabinol Use in Patients With Insomnia Disorder

CUPID
Start date: August 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to investigate the acute effects of cannabinol (CBN) 30 mg and 300 mg, versus placebo, on sleep architecture and next-day functioning in adults aged 25-65 years with chronic insomnia disorder.

NCT ID: NCT05344157 Active, not recruiting - Clinical trials for Osteoarthritis, Knee

A First-in-Human Study of XSTEM-OA in Patients With Knee Osteoarthritis

Start date: June 22, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of the study is to assess safety, tolerability and preliminary efficacy of XSTEM-OA when administered as a single intra-articular injection to patients with symptomatic knee osteoarthritis. The study is divided into two parts; a dose escalation (Part A) and an optional dose expansion part (Part: B). Three dose levels are planned to be evaluated in Part A and selected dose level(s) may be further expanded in Part B.

NCT ID: NCT05343637 Completed - Clinical trials for Pulmonary Arterial Hypertension

A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension

Start date: July 30, 2019
Phase: Phase 2
Study type: Interventional

This multicenter, open label, Phase 2a study is designed to evaluate the effect of inhaled RT234 delivered in a dose escalation manner on the change in pulmonary vascular resistance (PVR) in subjects with Pulmonary Arterial Hypertension (PAH) undergoing Right heart catheterization (RHC). This study is also known as Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2a (VIPAH-PRN 2a) study

NCT ID: NCT05340790 Recruiting - Bacterial Vaginosis Clinical Trials

First in Human Study in Healthy Volunteers of Antimicrobial Peptide PL-18 Vaginal Suppositories

Start date: August 1, 2022
Phase: Phase 1
Study type: Interventional

This is a Single-center, Randomized, Double-blind, Placebo-controlled Phase I Study to Evaluate the Safety, Tolerability and PK Profiles of Single and Multiple Ascending Doses of Antimicrobial Peptide PL-18 Vaginal Suppositories.